Bartunek Jozef, Wijns William, Heyndrickx Guy R, Vanderheyden Marc
Cardiovascular Center, OLV Ziekenhuis, Aalst, Belgium.
Nat Clin Pract Cardiovasc Med. 2006 Mar;3 Suppl 1:S52-6. doi: 10.1038/ncpcardio0417.
It is still unclear whether the timing of intracoronary stem cell therapy affects the therapeutic response in patients with reperfused myocardial infarction. The natural course of healing the infarction and the presence of putative homing signals within the damaged myocardium appear to favor cell engraftment during the transendothelial passage in the early days after reperfusion. However, the adverse inflammatory environment, with its high oxidative stress, might be deleterious if cells are administered too early after reperfusion. In addition, current studies use mostly unfractionated cells and it remains to be addressed whether specific cell types, and their enrichment, would be better suited to augmenting the recovery at later time points. Here we highlight several aspects of the timing of intracoronary stem cell therapy and focus on time-related questions that are relevant to the design of future experimental and basic studies.
冠状动脉内干细胞治疗的时机是否会影响再灌注心肌梗死患者的治疗反应仍不清楚。梗死愈合的自然过程以及受损心肌中假定的归巢信号似乎有利于在再灌注后早期经内皮通道过程中的细胞植入。然而，如果在再灌注后过早给予细胞，具有高氧化应激的不良炎症环境可能是有害的。此外，目前的研究大多使用未分级的细胞，特定细胞类型及其富集是否更适合在后期增强恢复仍有待解决。在这里，我们强调冠状动脉内干细胞治疗时机的几个方面，并关注与未来实验和基础研究设计相关的时间相关问题。
